V. de Lorenzo  Clinical Microbiology and Infection 

Slides:



Advertisements
Similar presentations
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Advertisements

Vaccines for the elderly
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
L. Boyanova  Clinical Microbiology and Infection 
R. Cantón, A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero, T
C.N. van Ettekoven, D. van de Beek, M.C. Brouwer 
Gut bacterial microbiota and obesity
I.J. Schalk  Clinical Microbiology and Infection 
Varicella vaccination: a laboured take-off
S. Wagenpfeil, A. Neiss, K. Banz, P. Wutzler 
The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria  M.J. Rybak  Clinical Microbiology and Infection 
Migrant health—a cause for concern?
Clinical characteristics of Haemophilus influenzae meningitis in Denmark in the post- vaccination era  T.I. Pedersen, M. Howitz, C. Østergaard  Clinical.
A. Moya, R. Gil, A. Latorre  Clinical Microbiology and Infection 
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
J.-P. Van geertruyden  Clinical Microbiology and Infection 
R. Cantón  Clinical Microbiology and Infection 
Genital Chlamydia trachomatis infections
P. Balraj, G. Vestris, D. Raoult, P. Renesto 
Louis Pasteur, from crystals of life to vaccination
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
Non-antibiotic strategies for sepsis
Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice?  T. Coenye, D. Goeres, F. Van Bambeke, T. Bjarnsholt 
Surveillance of Legionnaires’ disease in Austria
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
Vector control: a cornerstone in the malaria elimination campaign
J.P. Donnelly, B.E. De Pauw  Clinical Microbiology and Infection 
New Delhi metallo-beta-lactamase (NDM-1): towards a new pandemia?
Training for the infectious diseases speciality in Norway
A. Fajardo, J.F. Linares, J.L. Martínez 
R. Karakus, K. Caglar, C. Aybay  Clinical Microbiology and Infection 
B. Gordts  Clinical Microbiology and Infection 
Integrons and gene cassettes in clinical isolates of co-trimoxazole-resistant Gram- negative bacteria  M. Grape, A. Farra, G. Kronvall, L. Sundström  Clinical.
CMI editorial report 2011 Clinical Microbiology and Infection
Comparison of clinical and environmental isolates of Legionella pneumophila obtained in the UK over 19 years  T.G. Harrison, N. Doshi, N.K. Fry, C.A.
Elements of design: the knowledge on which we build
Coupled microbial and human systems: evidence for a relationship between infectious disease and gross national product  T.G. Bromage  Clinical Microbiology.
In vitro selection of antibiotic resistance in Pseudomonas aeruginosa
Levofloxacin in the treatment of ventilator-associated pneumonia
Metagenomics and probiotics
A case of pleurisy associated with antibodies to Rickettsia conorii
S8 – S47 and O50 – O440 Clinical Microbiology and Infection
Pathogenesis of catheter-related infections: lessons for new designs
T.M. File  Clinical Microbiology and Infection 
Antibacterial drug discovery in the 21st century
Abstracts cont. Clinical Microbiology and Infection
Pandemic lineages of extraintestinal pathogenic Escherichia coli
Training in infectious diseases and tropical medicine in Britain
A.P. Underwood, J. Green  Clinical Microbiology and Infection 
Antimicrobial drug development – the past, the present, and the future
Vaccines for the elderly
R. Cantón, A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero, T
Statin use and clinical outcomes among pneumonia patients
Listeriosis: a resurgent foodborne infection
I. Bitar, A. Piazza  Clinical Microbiology and Infection 
K. Kaier, N.T. Mutters, U. Frank  Clinical Microbiology and Infection 
Panton–Valentine leukocidin-encoding bacteriophage and gene sequence variation in community-associated methicillin-resistant Staphylococcus aureus  J.A.
The atypical pneumonias: clinical diagnosis and importance
Abstracts Clinical Microbiology and Infection
A. Ramette, J.M. Tiedje, A. Boetius 
Modelling during an emergency: the 2009 H1N1 influenza pandemic
New oral cephalosporins in pediatric community-acquired infections
B.A. Cunha  Clinical Microbiology and Infection 
J.L. Balcázar  Clinical Microbiology and Infection 
G.C. Schito  Clinical Microbiology and Infection 
Impact of antibiotic restrictions: the patient's perspective
C. Socolovschi, D. Raoult, P. Parola 
Comparative study of pediculicidal effect of medical plants
CMI readers' survey Clinical Microbiology and Infection
The future of diagnostic bacteriology
Presentation transcript:

Recombinant bacteria for environmental release: what went wrong and what we have learnt from it  V. de Lorenzo  Clinical Microbiology and Infection  Volume 15, Pages 63-65 (January 2009) DOI: 10.1111/j.1469-0691.2008.02683.x Copyright © 2009 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 Factors that affect expression in vivo of the sigma-54-dependent promoter Pu of the TOL plasmid pWW0 of m-xylene-degrading Pseudomonas putida mt-2. Pu can be transcribed in vitro by combining purified IHF, the sigma factor core RNAP and activated XylR. However, the same promoter is subject in vivo to a plethora of additional factors and inputs, which influence to various degrees the activity of Pu under diverse growth or stress conditions. Mechanistically, such signals enter through the integration host factor (IHF), the IIANtr protein, sigma factor competition, ppGpp levels, temperature, the TurA histone-like proteins, and perhaps other additional inputs. Clinical Microbiology and Infection 2009 15, 63-65DOI: (10.1111/j.1469-0691.2008.02683.x) Copyright © 2009 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 2 Engineering bacterial consortia with adhesins á la carte. Bacteria A, B and C, which are unable to degrade a given chemical, may, however, bear genes encoding enzymes which, when put together, can give rise to a novel metabolic pathway. However, such bacteria may not naturally have any tendency to associate with each other (right). However, consortia can be forced to form by expressing on the surface of the cells specific adhesins (e.g. single-chain antibodies) anchored to the cell envelope with autotransporter domains (right; see text for explanation). Clinical Microbiology and Infection 2009 15, 63-65DOI: (10.1111/j.1469-0691.2008.02683.x) Copyright © 2009 European Society of Clinical Infectious Diseases Terms and Conditions